Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vertex price target raised to $330 from $290 at Goldman Sachs » 07:13
07/02/20
07/02
07:13
07/02/20
07:13
VRTX

Vertex

$286.30 /

-4.24 (-1.46%)

, CRSP

Crispr Therapeutics

$78.50 /

+5.21 (+7.11%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter raised the firm's price target on Vertex Pharmaceuticals (VRTX) to $330 from $290 and keeps a Conviction Buy rating on the shares. The stock's 31% rally year-to-date is due to earnings execution on the cystic fibrosis franchise through lead revenue driver Trikafta, Richter tells investors in a research note. At current share levels, the analyst sees Vertex's cystic fibrosis opportunity as "largely appreciated." As such, Richter is turning to the company's "multi-modality pipeline as the next lever for growth." Following the positive Crispr Therapeutics (CRSP) partnered Phase 1/2 CTX001 CRISPR/Cas9 gene editing data in transfusion-dependent beta thalassemia and severe sickle cell disease, as well as a "supporting" physician survey, Richter introduced the program into the model at a 60% probability of success. Further, the analyst continues to see "significant opportunity" in Vertex's Phase 2 alpha-1 antitrypsin deficiency disorder program.

ShowHide Related Items >><<
VRTX Vertex
$286.30 /

-4.24 (-1.46%)

CRSP Crispr Therapeutics
$78.50 /

+5.21 (+7.11%)

VRTX Vertex
$286.30 /

-4.24 (-1.46%)

07/01/20 Jefferies
Vertex reimbursement in England 'a remarkable positive,' says Jefferies
06/26/20 Piper Sandler
Piper says EU approval can help drive next leg of CF growth at Vertex
06/24/20 SunTrust
Vertex price target raised to $330 from $285 at SunTrust
06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
CRSP Crispr Therapeutics
$78.50 /

+5.21 (+7.11%)

06/29/20 Piper Sandler
Crispr Therapeutics remains a top pick for 2020 at Piper Sandler
06/23/20 Oppenheimer
Crispr Therapeutics price target raised to $89 from $80 at Oppenheimer
06/22/20 Piper Sandler
Piper Sandler reiterates Overweight on Crispr following AACR posters
06/19/20 Piper Sandler
Crispr Therapeutics initiates Phase I/II study of CTX130, says Piper Sandler
VRTX Vertex
$286.30 /

-4.24 (-1.46%)

CRSP Crispr Therapeutics
$78.50 /

+5.21 (+7.11%)

  • 01
    Jul
  • 21
    Nov
VRTX Vertex
$286.30 /

-4.24 (-1.46%)

CRSP Crispr Therapeutics
$78.50 /

+5.21 (+7.11%)

VRTX Vertex
$286.30 /

-4.24 (-1.46%)

Wednesday
Recommendations
Vertex reimbursement in England 'a remarkable positive,' says Jefferies » 08:35
07/01/20
07/01
08:35
07/01/20
08:35
VRTX

Vertex

$290.54 /

+5.37 (+1.88%)

After Vertex announced a…

After Vertex announced a reimbursement agreement with England to include the new triple pill Kaftrio, Jefferies analyst Michael Yee called the news "a remarkable positive and first time we've seen England move this fast," noting that the agreement came several months ahead of the expected triple pill approval in the EU and the fact that the U.K. is typically one of the more challenging countries for reimbursement. Yee, who calls this pact an incremental positive, keeps a Buy rating and $295 price target on Vertex shares.

ShowHide Related Items >><<
VRTX Vertex
$290.54 /

+5.37 (+1.88%)

VRTX Vertex
$290.54 /

+5.37 (+1.88%)

06/26/20 Piper Sandler
Piper says EU approval can help drive next leg of CF growth at Vertex
06/24/20 SunTrust
Vertex price target raised to $330 from $285 at SunTrust
06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
VRTX Vertex
$290.54 /

+5.37 (+1.88%)

VRTX Vertex
$290.54 /

+5.37 (+1.88%)

VRTX Vertex
$290.54 /

+5.37 (+1.88%)

Tuesday
Hot Stocks
Vertex announces reimbursement agreement with NHS England » 08:41
06/30/20
06/30
08:41
06/30/20
08:41
VRTX

Vertex

$285.17 /

-1.05 (-0.37%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals announced that it has expanded its reimbursement agreement with NHS England for Vertex's cystic fibrosis medicines to include KAFTRIO, in a combination regimen with KALYDECO 150 mg, ahead of the medicine's anticipated approval by the European Commission. Vertex said in a release, "The new expanded agreement includes reimbursed access to Vertex's currently licensed medicines - KALYDECO, ORKAMBI and SYMKEVI, as well as the triple combination therapy if approved - and any future additional licensed indications for all of these medicines."

ShowHide Related Items >><<
VRTX Vertex
$285.17 /

-1.05 (-0.37%)

VRTX Vertex
$285.17 /

-1.05 (-0.37%)

06/26/20 Piper Sandler
Piper says EU approval can help drive next leg of CF growth at Vertex
06/24/20 SunTrust
Vertex price target raised to $330 from $285 at SunTrust
06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
VRTX Vertex
$285.17 /

-1.05 (-0.37%)

VRTX Vertex
$285.17 /

-1.05 (-0.37%)

VRTX Vertex
$285.17 /

-1.05 (-0.37%)

Over a week ago
Recommendations
Piper says EU approval can help drive next leg of CF growth at Vertex » 11:09
06/26/20
06/26
11:09
06/26/20
11:09
VRTX

Vertex

$287.22 /

-8.05 (-2.73%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff noted that the CHMP of the European Medicines Agency has issued a positive opinion for the Kaftrio triple therapy, adding that he is confident in European approval for the combo. EU approval could add 10,000 het-min patients who never had therapy and drive the next leg of cystic fibrosis growth for Vertex, said Tenthoff, who reiterates an Overweight rating and $302 price target on the shares.

ShowHide Related Items >><<
VRTX Vertex
$287.22 /

-8.05 (-2.73%)

VRTX Vertex
$287.22 /

-8.05 (-2.73%)

06/24/20 SunTrust
Vertex price target raised to $330 from $285 at SunTrust
06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
VRTX Vertex
$287.22 /

-8.05 (-2.73%)

VRTX Vertex
$287.22 /

-8.05 (-2.73%)

VRTX Vertex
$287.22 /

-8.05 (-2.73%)

Hot Stocks
Vertex announces CHMP positive opinion for KAFTRIO » 08:26
06/26/20
06/26
08:26
06/26/20
08:26
VRTX

Vertex

$295.27 /

+4.37 (+1.50%)

Vertex Pharmaceuticals…

Vertex Pharmaceuticals announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, adopted a positive opinion for KAFTRIO in a combination regimen with KALYDECO 150 mg to treat people with cystic fibrosis, or CF, ages 12 and older with one F508del mutation and one minimal function mutation, or F/MF, or two F508del mutations, or F/F, in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Vertex said in a release, "If approved, up to 10,000 people in Europe with CF ages 12 and older who have one F508del mutation and one minimal function mutation would be newly eligible for a medicine that targets the disease- causing protein defect. Additionally, people 12 years of age and older who have two F508del mutations and who are currently eligible for one of Vertex's other EMA-approved cystic fibrosis medicines would be eligible for the new triple combination regimen. The CHMP positive opinion was based on the results of two global Phase 3 studies in people with CF: a 24-week placebo-controlled study in people ages 12 years and older with one F508del mutation and one minimal function mutation and a 4-week head-to-head study of the triple combination therapy in comparison to tezacaftor/ivacaftor in people ages 12 years and older with two F508del mutations. Both Phase 3 studies showed statistically significant and clinically meaningful improvements in lung function (percent predicted forced expiratory volume in one second; ppFEV1), which was the primary endpoint, and in all key secondary endpoints. In both studies, the ivacaftor/tezacaftor/elexacaftor plus ivacaftor combination regimen was generally well tolerated."

ShowHide Related Items >><<
VRTX Vertex
$295.27 /

+4.37 (+1.50%)

VRTX Vertex
$295.27 /

+4.37 (+1.50%)

06/24/20 SunTrust
Vertex price target raised to $330 from $285 at SunTrust
06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
VRTX Vertex
$295.27 /

+4.37 (+1.50%)

VRTX Vertex
$295.27 /

+4.37 (+1.50%)

VRTX Vertex
$295.27 /

+4.37 (+1.50%)

Recommendations
Vertex price target raised to $330 from $285 at SunTrust » 09:16
06/24/20
06/24
09:16
06/24/20
09:16
VRTX

Vertex

$295.95 /

+2.6 (+0.89%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas raised the firm's price target on Vertex to $330 from $285 and keeps a Buy rating on the shares. The analyst is updating her model to reflect the company's Trikafta launch metrics, along with additional color from the management on the launch and its conversion dynamics in the U.S. Cystic fibrosis market in the U.S. is approaching a plateau, but there is potential for continued growth in international markets from approval and country-based reimbursement agreements for Trikafta, the analyst tells investors in a research note.

ShowHide Related Items >><<
VRTX Vertex
$295.95 /

+2.6 (+0.89%)

VRTX Vertex
$295.95 /

+2.6 (+0.89%)

06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
VRTX Vertex
$295.95 /

+2.6 (+0.89%)

VRTX Vertex
$295.95 /

+2.6 (+0.89%)

VRTX Vertex
$295.95 /

+2.6 (+0.89%)

Hot Stocks
Solid Biosciences appoints Ian Smith as chairman of board » 07:04
06/18/20
06/18
07:04
06/18/20
07:04
SLDB

Solid Biosciences

$3.04 /

+0.015 (+0.50%)

, VRTX

Vertex

$280.48 /

+6.92 (+2.53%)

Solid Biosciences (SLDB)…

Solid Biosciences (SLDB) announced the appointment of board member Ian Smith as chairman of the board. Smith succeeds Andrey Zarur, Ph.D., who served as chairman of the board since 2013 and is one of the co-founders of Solid Biosciences. The appointment is effective June 16, 2020. Smith most recently serving as EVP and COO of Vertex Pharmaceuticals (VRTX).

ShowHide Related Items >><<
VRTX Vertex
$280.48 /

+6.92 (+2.53%)

SLDB Solid Biosciences
$3.04 /

+0.015 (+0.50%)

SLDB Solid Biosciences
$3.04 /

+0.015 (+0.50%)

05/08/20 Nomura Instinet
Solid Biosciences price target lowered to $6 from $10 at Nomura Instinet
05/07/20 Evercore ISI
Solid Biosciences downgraded to In Line from Outperform at Evercore ISI
12/19/19 SVB Leerink
Solid data 'underwhelming,' SGT-001 path forward unclear, says SVB Leerink
12/18/19 Nomura Instinet
Solid Biosciences price target raised to $10 from $6 at Nomura Instinet
VRTX Vertex
$280.48 /

+6.92 (+2.53%)

06/12/20 Piper Sandler
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler
06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
VRTX Vertex
$280.48 /

+6.92 (+2.53%)

VRTX Vertex
$280.48 /

+6.92 (+2.53%)

VRTX Vertex
$280.48 /

+6.92 (+2.53%)

Recommendations
Crispr update suggests 'potential curative effect' of CTX001, says Piper Sandler » 09:19
06/12/20
06/12
09:19
06/12/20
09:19
CRSP

Crispr Therapeutics

$59.77 /

-3.3 (-5.23%)

, VRTX

Vertex

$263.73 /

-10.45 (-3.81%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff noted that Crispr Therapeutics (CRSP) and partner Vertex (VRTX) updated Phase I/II CTX001 data on two transfusion-dependent beta-thalassemia patients and one sickle cell disease patient at the virtual EHA conference. The update shows continued durable response, suggesting the "potential curative effect of CTX001," according to Tenthoff, who reiterates his Overweight rating and $104 price target on Crispr shares following the release of the data.

ShowHide Related Items >><<
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

06/10/20 Stifel
Stifel says Bluebird setup 'downside biased,' Crispr's 'upside biased' into EHA
04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
04/28/20
RBC Capital downgraded Vertex to Sector Perform on valuation
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

Hot Stocks
Crispr Therapeutics, Vertex announce new CTX001 data from CLIMB trials » 06:25
06/12/20
06/12
06:25
06/12/20
06:25
CRSP

Crispr Therapeutics

$59.77 /

-3.3 (-5.23%)

, VRTX

Vertex

$263.73 /

-10.45 (-3.81%)

Crispr Therapeutics…

Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia, or TDT, and severe sickle cell disease, or SCD, and highlighted recent progress in the CTX001 development program. These data were presented during an oral presentation at the European Hematology Association, or EHA. Data presented at EHA demonstrate clinical proof-of-concept for CTX001 in TDT. Data include longer-duration follow-up data for the first patient with TDT treated with CTX001 and new data for the second TDT patient treated. CRISPR Therapeutics and Vertex announced initial data for the first TDT patient in November of 2019. Patient 1 with TDT has the ss0/IVS-I-110 genotype, which is associated with a severe phenotype similar to ss0/ss0, and had a transfusion requirement of 34 units of packed red blood cells per year before enrolling in the clinical trial. As previously reported, the patient achieved neutrophil engraftment 33 days after CTX001 infusion and platelet engraftment 37 days after infusion. After CTX001 infusion, two serious adverse events, or SAEs, occurred, neither of which the principal investigator, or PI, considered related to CTX001: pneumonia in the presence of neutropenia, and veno-occlusive liver disease attributed to busulfan conditioning; both subsequently resolved. New data presented show that at 15 months after CTX001 infusion, the patient was transfusion independent and had total hemoglobin levels of 14.2 g/dL, fetal hemoglobin of 13.5 g/dL, and F-cells of 100%. Bone marrow allelic editing was 78.1% at 6 months and 76.1% at one year. Patient 2 with TDT has the ss0/IVS-II-745 genotype and had a transfusion requirement of 61 units of packed red blood cells per year before enrolling in the clinical trial. The patient achieved neutrophil engraftment 36 days after CTX001 infusion and platelet engraftment 34 days after infusion. After CTX001 infusion, two SAEs occurred, neither of which the PI considered related to CTX001: pneumonia and an upper respiratory tract infection; both subsequently resolved. At 5 months after CTX001 infusion, the patient was transfusion independent and had total hemoglobin levels of 12.5 g/dL, fetal hemoglobin of 12.2 g/dL, and F-cells of 99.4%. Data presented at EHA reflect longer-duration follow-up data for the first patient with SCD treated with CTX001. Crispr Therapeutics and Vertex announced initial data for this first SCD patient in November of 2019.Patient 1 with SCD experienced seven vaso-occlusive crises , or VOCs, and five packed red blood cell transfusions per year before enrolling in the clinical trial. As previously reported, the patient achieved neutrophil and platelet engraftment 30 days after CTX001 infusion. After CTX001 infusion, three SAEs occurred, none of which the PI considered related to CTX001: sepsis in the presence of neutropenia, cholelithiasis and abdominal pain; all subsequently resolved. New data presented today show that at 9 months after CTX001 infusion, the patient was free of VOCs, was transfusion independent and had total hemoglobin levels of 11.8 g/dL, 46.1% fetal hemoglobin, and F-cells of 99.7%. Bone marrow allelic editing was 81.4% at 6 months. Figure 2 presents the hemoglobin data over time for this patient. CLIMB-111 for TDT has dosed a total of 5 patients, and all patients have successfully engrafted. The trial is also now open for concurrent dosing after successful dosing and engraftment of the first two patients. Additionally, CLIMB-111 has been expanded to allow enrollment of beta0/beta0 patients and is in the process of being expanded to allow enrollment of pediatric patients ages 12 years or older. CLIMB-121 for SCD has dosed a total of 2 patients and both patients have successfully engrafted. The trial is also now open for concurrent dosing after successful dosing and engraftment of these first two patients. The initial safety profile in these trials appears to be consistent with myeloablative busulfan conditioning and an autologous hematopoietic stem cell transplant. In March, clinical trial sites in the U.S. and Europe temporarily paused their elective hematopoietic stem cell transplant programs due to the COVID-19 pandemic, and as a result, Crispr and Vertex temporarily paused conditioning and dosing in these trials. Enrollment, mobilization and drug product manufacturing in each trial remains ongoing. The companies are now in the process of re-initiating dosing with CTX001 at certain clinical trial sites. The CLIMB-111 and CLIMB-121 clinical trials are ongoing, and patients will be followed for 2 years following CTX001 infusion. The companies expect to provide additional data in the second half of 2020.

ShowHide Related Items >><<
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

06/10/20 Stifel
Stifel says Bluebird setup 'downside biased,' Crispr's 'upside biased' into EHA
04/29/20 Raymond James
Crispr progress not enough to change bearish view, says Raymond James
04/28/20 Piper Sandler
Piper backs Overweight on Crispr after Q1 results
04/27/20 Piper Sandler
Piper backs Overweight on Vertex after new Affinia partnership
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

06/12/20 Citi
Vertex price target raised to $325 from $305 at Citi
04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
04/28/20
RBC Capital downgraded Vertex to Sector Perform on valuation
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

CRSP Crispr Therapeutics
$59.77 /

-3.3 (-5.23%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

Recommendations
Vertex price target raised to $325 from $305 at Citi » 05:59
06/12/20
06/12
05:59
06/12/20
05:59
VRTX

Vertex

$263.73 /

-10.45 (-3.81%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal raised the firm's price target on Vertex to $325 from $305 and keeps a Buy rating on the shares, calling it his top pick in large cap pharmaceuticals given the "trifecta" of a growing base business, long patent life for its base and a robust pipeline. The company's pipeline for focal segmental glomerulosclerosis and opportunities in Type1 Diabetes, along with its CRISPR programs, are some of the longer-term opportunities Bansal highlighted in his note about its pipeline diversification.

ShowHide Related Items >><<
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

04/30/20 SVB Leerink
Vertex price target raised to $263 from $224 at SVB Leerink
04/30/20 H.C. Wainwright
Vertex price target raised to $295 from $270 at H.C. Wainwright
04/28/20
RBC Capital downgraded Vertex to Sector Perform on valuation
04/28/20 RBC Capital
Vertex downgraded to Sector Perform from Outperform at RBC Capital
VRTX Vertex
$263.73 /

-10.45 (-3.81%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

VRTX Vertex
$263.73 /

-10.45 (-3.81%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.